BlossomHill Therapeutics, Inc. BLSM
16.12 USD +1.88 (+13.20%)
At closeNov 11, 2026, 4:00 PM EST
16.12 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
14.48 Day range 16.19
11.02 52-week range 27.99
- YTD
- +0.75%
- 1 year
- +0.75%
- Market cap
- 512.37M
- EPS (ttm)
- -4.70
- YTD return
- +0.75%
- 1-year return
- +0.75%
- Volume
- 203.68K
- Avg volume
- 193.63K
- Open
- 14.48
- Previous close
- 14.24
- Day's range
- 14.48 – 16.19
- 52-week range
- 11.02 – 27.99
5D +1.64 (+13.02%)
Financials — quick view
BLSM Revenue — quarterly 0
BLSM Net income — quarterly -23.76M
BLSM EPS — quarterly -8.75
News
BlossomHill Therapeutics Announces Alignment With FDA On 50mg Twice Daily As Recommended Phase 2 Dose For BH-30643 
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC 
BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation 
BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027 
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40 - Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
Earnings Scheduled For September 18, 2026 
BlossomHill Therapeutics Q2 EPS $(8.75) 
BlossomHill Therapeutics Announces Updated Data From Ongoing Phase 1/2 SOLARA Trial Of BH-30643 In NSCLC Patients With Secondary EGFR Resistance Mutations Such As EGFR C797S - LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32
Your note
Sign in to keep a note on BLSM — it syncs with the Stock Master app.